ProductHighlights:
ComparedtothecurrentACMGrecommendedcysticfibrosisvariantpanel,theMiSeqDxCysticFibrosis139-VariantAssayoffers:
- ImprovedDetectionRatesofCysticFibrosis-CausingVariants
Detectionofcouplesatriskincreasedfrom72%to~91%1 - ReducedAdditionalTesting
HighlyaccurateandreproducIBLesequencingtechnologydeliversdependableresults
TheMiSeqDxCysticFibrosis139-VariantAssayisanFDA-clearedinvitrodiagnostic(IVD)next-generationsequencingtestdesignedtodetect139CFTRvariantsasdefinedintheCFTR2database.OthermethodstestonlyforthosevariantsmostcommonlyfoundinCaucasians,potentiallymissingCF-causingvariantsacrossbroaderethnicgroups.TheMiSeqDxCysticFibrosis139-VariantAssayoffersthelargestCFvariantpaneltoovercomethisbiasandprovidecomprehensivedetectionacrossdiversedemographics.2
Widelyadoptednext-generationsequencing
TheMiSeqDxCysticFibrosis139-VariantAssayprovidesafullyintegratedmolecularCFtestingsolutionontheMiSeqDxinstrument.Simplypreparelibrariesfrom250nggDNA,loadontotheMiSeqDxforsequencingusingIlluminasequencingbysynthesis(SBS)chemistry,andanalyzewiththeuser-friendlysoftware.Theautomatedworkflowisquickandeasytoperform,potentiallyminimizinghumanerror.
Acompletekitforlibrarypreparationandsequencing
TheMiSeqDxCysticFibrosis139-VariantAssayincludesallindexprimersandreagentsneededforlibrarypreparation,samplemultiplexing,andsequencinginasinglekit.MiSeqDxsequencingreagentsarepackagedinaconvenientready-to-useformat,minimizinghands-ontimeandincreasinguniformityinalltests.Toaccommodateabroadspectrumoftestingneeds,fromsmalltolargevolumes,theassayisavailableintwokitconfigurations(2or20runs).
Specifications:
| AssayTime | 2.5days |
| Hands-OnTime | 3.5hours |
| InputQuantity | 250nggenomicDNA |
| SystemCompatibility | MiSeqDx |
| Technology | Sequencing |
